Avalo Therapeutics (AVTX) Current Assets (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Current Assets came in at $88.8 million in Q1 2026, down 30.03% YoY from $126.9 million in Q1 2025, and down 15.63% on a QoQ basis from $105.3 million in Q4 2025.
Avalo Therapeutics (AVTX) Current Assets (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Current Assets data on file, last reported at $88.8 million in Q1 2026.
- Quarterly Current Assets fell 30.03% year-over-year to $88.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.8 million (down 30.03% YoY) and the FY2025 annual result came in at $105.3 million, down 24.19% from the prior year.
- Current Assets declined to $88.8 million in Q1 2026, from $105.3 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $138.9 million in Q4 2024 to a low of $7.5 million in Q2 2023.
- A 5-year average of $66.2 million and a median of $86.1 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets plunged 74.74% — and 2024, when it jumped 1554.44%.
- Tracing AVTX's Current Assets over 5 years: stood at $16.4 million in 2022, then sank by 48.86% to $8.4 million in 2023, then jumped by 1554.44% to $138.9 million in 2024, then fell by 24.19% to $105.3 million in 2025, then declined by 15.63% to $88.8 million in 2026.
- The last three Current Assets figures came in at $88.8 million (Q1 2026), $105.3 million (Q4 2025), and $113.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 407.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 407.93 Mn |
| Mar 31, 2026 | 88.83 Mn |
| Dec 31, 2025 | 105.29 Mn |
| Sep 30, 2025 | 113.85 Mn |
| Jun 30, 2025 | 115.19 Mn |
| Mar 31, 2025 | 126.94 Mn |
| Dec 31, 2024 | 138.89 Mn |
| Sep 30, 2024 | 86.15 Mn |
| Jun 30, 2024 | 95.89 Mn |
| Mar 31, 2024 | 111.21 Mn |
| Dec 31, 2023 | 8.40 Mn |
| Sep 30, 2023 | 12.66 Mn |
| Jun 30, 2023 | 7.52 Mn |
| Mar 31, 2023 | 19.25 Mn |
| Dec 31, 2022 | 16.42 Mn |
| Sep 30, 2022 | 19.45 Mn |
| Jun 30, 2022 | 15.02 Mn |
| Mar 31, 2022 | 43.66 Mn |
| Dec 31, 2021 | 61.85 Mn |
| Sep 30, 2021 | 77.01 Mn |